{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:14Z","timestamp":1792789754856,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijcard.2021.11.008","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T10:50:15Z","timestamp":1636714215000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study"],"prefix":"10.1016","volume":"346","author":[{"given":"X.L.","family":"Marston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-C.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Br\u00fcggenj\u00fcrgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unverdorben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ijcard.2021.11.008_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/heartjnl-2018-313350","article-title":"Global rising trends of atrial fibrillation: a major public health concern","volume":"104","author":"Patel","year":"2018","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.ijcard.2021.11.008_bb0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"9989","key":"10.1016\/j.ijcard.2021.11.008_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2021.11.008_bb0020","author":"Kumar"},{"issue":"23","key":"10.1016\/j.ijcard.2021.11.008_bb0025","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.ijcard.2021.11.008_bb0030","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2021.11.008_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.ijcard.2021.11.008_bb0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/europace\/eus333","article-title":"Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients","volume":"15","author":"Wilke","year":"2013","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.ijcard.2021.11.008_bb0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ijcard.2021.11.008_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor's choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.008_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12875-018-0796-4","article-title":"Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction","volume":"19","author":"Schwill","year":"2018","journal-title":"BMC Fam. Pract."},{"issue":"22","key":"10.1016\/j.ijcard.2021.11.008_bb0060","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"Supplement_2","key":"10.1016\/j.ijcard.2021.11.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.0401","article-title":"Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study","volume":"41","author":"Marston","year":"2020","journal-title":"Eur. Heart J."},{"issue":"Supplement 1","key":"10.1016\/j.ijcard.2021.11.008_bb0070","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jval.2020.04.184","article-title":"Comparison of treatment adherence and persistence with edoxaban versus apibaxan, dabigatran, rivaroxaban, and vitamin K antagonist in non-valvulvar atrial fibrillation patients in Germany: a propensity-matched cohort study","volume":"23","author":"Wang","year":"2020","journal-title":"Value Health"},{"issue":"Supplement_2","key":"10.1016\/j.ijcard.2021.11.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.0455","article-title":"Improved adherence to anticoagulant therapy with once-daily regimen: a real-world study in patients with atrial fibrillation in Germany","volume":"41","author":"Yeh","year":"2020","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.ijcard.2021.11.008_bb0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 european heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2021.11.008_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.ijcard.2021.11.008_bb0090","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.ijcard.2021.11.008_bb0095","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.008_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jjcc.2019.06.007","article-title":"HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: a subanalysis of the Japanese anti-coagulation regimen exploration in AF catheter ablation registries","volume":"75","author":"Inoue","year":"2020","journal-title":"J. Cardiol."},{"issue":"22","key":"10.1016\/j.ijcard.2021.11.008_bb0105","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.ijcard.2021.11.008_bb0110","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijcard.2021.11.008_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2021.11.008_bb0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ijcard.2021.11.008_bb0125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/MLR.0000000000000901","article-title":"Health care costs and utilization of dabigatran compared with warfarin for secondary stroke prevention in patients with nonvalvular atrial fibrillation: a retrospective population study","volume":"56","author":"Chi","year":"2018","journal-title":"Med. Care"},{"issue":"3","key":"10.1016\/j.ijcard.2021.11.008_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"issue":"3","key":"10.1016\/j.ijcard.2021.11.008_bb0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2013040361","article-title":"Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD","volume":"25","author":"Harel","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000279","article-title":"NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis","volume":"3","author":"Hicks","year":"2016","journal-title":"Open Heart."},{"issue":"05","key":"10.1016\/j.ijcard.2021.11.008_bb0145","first-page":"981","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation.An indirect comparison analysis","volume":"111","author":"Skj\u00f8th","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ijcard.2021.11.008_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12874-019-0695-y","article-title":"Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review","volume":"19","author":"Prada-Ramallal","year":"2019","journal-title":"BMC Med. Res. Methodol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321017769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321017769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:55:02Z","timestamp":1759092902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321017769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"alternative-id":["S0167527321017769"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.008","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}